IL296380A - Therapeutic uses of l-4-chlorokynurenine - Google Patents

Therapeutic uses of l-4-chlorokynurenine

Info

Publication number
IL296380A
IL296380A IL296380A IL29638022A IL296380A IL 296380 A IL296380 A IL 296380A IL 296380 A IL296380 A IL 296380A IL 29638022 A IL29638022 A IL 29638022A IL 296380 A IL296380 A IL 296380A
Authority
IL
Israel
Prior art keywords
chlorokynurenine
depression
dose
diabetes
treatment
Prior art date
Application number
IL296380A
Other languages
English (en)
Hebrew (he)
Inventor
Ralph Snodgrass H
Original Assignee
Vistagen Therapeutics Inc
Ralph Snodgrass H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc, Ralph Snodgrass H filed Critical Vistagen Therapeutics Inc
Publication of IL296380A publication Critical patent/IL296380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL296380A 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine IL296380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
IL296380A true IL296380A (en) 2022-11-01

Family

ID=57393671

Family Applications (3)

Application Number Title Priority Date Filing Date
IL296380A IL296380A (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine
IL255770A IL255770B (en) 2015-05-22 2017-11-20 Medicinal uses for l–4–chlorokynurenine
IL285882A IL285882A (en) 2015-05-22 2021-08-25 Medicinal uses for l–4–chlorokynurenine

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL255770A IL255770B (en) 2015-05-22 2017-11-20 Medicinal uses for l–4–chlorokynurenine
IL285882A IL285882A (en) 2015-05-22 2021-08-25 Medicinal uses for l–4–chlorokynurenine

Country Status (19)

Country Link
US (3) US20180140568A1 (enExample)
EP (2) EP4108239A1 (enExample)
JP (3) JP2018521007A (enExample)
KR (2) KR20240068766A (enExample)
CN (1) CN107949379A (enExample)
AU (3) AU2016268153B2 (enExample)
BR (1) BR112017024908A2 (enExample)
CA (1) CA3024783A1 (enExample)
DK (1) DK3297619T3 (enExample)
EA (1) EA201792571A1 (enExample)
ES (1) ES2925274T3 (enExample)
IL (3) IL296380A (enExample)
MX (1) MX395492B (enExample)
PL (1) PL3297619T3 (enExample)
PT (1) PT3297619T (enExample)
SG (1) SG10202007661XA (enExample)
SI (1) SI3297619T1 (enExample)
WO (1) WO2016191351A1 (enExample)
ZA (1) ZA201707874B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240812T1 (hr) 2013-01-22 2024-09-27 Vistagen Therapeutics, Inc. Oblici doziranja i terapijska primjena l-4-klorokinurenina
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
MX2021012383A (es) * 2019-04-09 2022-01-04 Vistagen Therapeutics Inc Variantes genéticas asociadas con la respuesta al tratamiento de trastornos neurológicos.
BR112022025901A2 (pt) * 2020-06-24 2023-01-10 Biohaven Therapeutics Ltd Composições e métodos para tratar transtorno obsessivo-compulsivo
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
BRPI0709984A2 (pt) * 2006-04-12 2011-08-02 Probiodrug Ag inibidores de enzima
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
CA2704475A1 (en) * 2007-11-06 2009-05-14 Emory University Methods of identifying improved nmda receptor antagonists
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
AU2013305580A1 (en) * 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
HRP20240812T1 (hr) * 2013-01-22 2024-09-27 Vistagen Therapeutics, Inc. Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
WO2014152752A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
WO2015171770A1 (en) * 2014-05-06 2015-11-12 Northwestern University Combinations of nmdar modulating compounds

Also Published As

Publication number Publication date
JP2018521007A (ja) 2018-08-02
KR20180015158A (ko) 2018-02-12
AU2023282234A1 (en) 2024-01-18
MX2017014456A (es) 2018-03-16
EA201792571A1 (ru) 2018-06-29
AU2016268153B2 (en) 2021-08-12
PL3297619T3 (pl) 2023-02-13
BR112017024908A2 (pt) 2018-07-31
EP3297619A1 (en) 2018-03-28
ZA201707874B (en) 2020-01-29
HK1257800A1 (en) 2019-11-01
CN107949379A (zh) 2018-04-20
SI3297619T1 (sl) 2023-02-28
IL285882A (en) 2021-09-30
US20190321317A1 (en) 2019-10-24
EP3297619B1 (en) 2022-07-06
IL255770A (en) 2018-01-31
US20180140568A1 (en) 2018-05-24
CA3024783A1 (en) 2016-12-01
WO2016191351A1 (en) 2016-12-01
MX395492B (es) 2025-03-25
EP3297619A4 (en) 2019-01-02
PT3297619T (pt) 2022-08-05
SG10202007661XA (en) 2020-09-29
AU2021209279B2 (en) 2023-09-14
KR20240068766A (ko) 2024-05-17
JP2022064908A (ja) 2022-04-26
DK3297619T3 (da) 2022-08-15
AU2016268153A1 (en) 2017-12-14
IL255770B (en) 2021-09-30
AU2021209279A1 (en) 2021-08-19
JP2024050575A (ja) 2024-04-10
EP4108239A1 (en) 2022-12-28
US20240122887A1 (en) 2024-04-18
ES2925274T3 (es) 2022-10-14

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
Winblad et al. Therapeutic use of nicergoline
AU2024203022A1 (en) LSD dose identification
KR20140041670A (ko) 행동 장애 및 정신 장애의 치료를 위한 실로―이노시톨
IL276126A (en) Compositions comprising l-4-chlorokynurenine and uses thereof
KR102776048B1 (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
JP2024519866A (ja) 神経学的疾患を治療するための方法及び組成物
US12622895B2 (en) Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
Zhang et al. Progress of non‐motor symptoms in early‐onset Parkinson's disease
MD3897578T2 (ro) Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC
JP2024507492A (ja) 精神療法を補助するためのメスカリン及びメスカリン類似体（スカリン）の効果
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
US20260083740A1 (en) Use of tavapadon in treating parkinson's disease
AU2017387713A1 (en) Variants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases
HK40060568A (en) Domperidone antineurodegenerative combinations and use
CN113365629A (zh) 多潘立酮抗神经退行性组合物及用途
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
DellaMarca andAlbertoAlbanese 10 sleep-related disorders